Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07114939 · ClinicalTrials.gov registry record · Phase 1
FTT PET/CT in Pancreatic Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07114939: Recruiting Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
NCT07114939 is a Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07114939, a Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
Primary Outcome
Evaluate the standard uptake value (SUV) of \[18F\]FTT in pancreatic neuroendocrine tumors (PanNETS). SUV is a measure of concentration of radioactivity/tracer in a specific tissue or organ usually calculated by weight or BMI.
Conditions Studied
Interventions
- DRUG [18F]FluorThanatrace
Study Locations (1)
Pennsylvania
- University of Pennsylvania, Perelman Center for Advanced Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT07114939 shows while recruiting
NCT07114939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Neuroendocrine Carcinoma Metastatic appearing as the primary indexed condition, and to 1 intervention - of which [18F]FluorThanatrace is the first listed.
NCT07114939 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07114939 about?
NCT07114939 is a clinical study titled "FTT PET/CT in Pancreatic Neuroendocrine Tumors". A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging asse...
What is the current status of trial NCT07114939?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-10-01. Estimated completion is 2027-09.
What conditions does trial NCT07114939 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors.
What interventions are being tested in trial NCT07114939?
The interventions under investigation include: [18F]FluorThanatrace (DRUG).
Who is sponsoring clinical trial NCT07114939?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07114939 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07114939's enrollment target sits among peer trials
12 1853rd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI